Literature DB >> 25744809

Ex vivo pharmacokinetic and pharmacodynamic analysis of valnemulin against Mycoplasma gallisepticum S6 in Mycoplasma gallisepticum and Escherichia coli co-infected chickens.

Xia Xiao1, Jian Sun1, Yi Chen1, Mengting Zou1, Dong-Hao Zhao1, Ya-Hong Liu2.   

Abstract

Pharmacokinetic and pharmacodynamic (PK/PD) indices against Mycoplasma gallisepticum (MG) S6 were investigated in an ex vivo PK/PD model following oral administration of valnemulin to chickens co-infected with M. gallisepticum and Escherichia coli. The minimum inhibitory concentrations (MICs) for valnemulin against MG S6 in artificial medium and chicken serum were determined. In vitro time-killing curves were established according to a series of multiples of the MIC value in an artificial medium, and ex vivo time-killing curves were established in serum samples obtained from infected chickens at different time points after oral administration with an initial titer of 1 × 10(6) color change units (CCU)/mL MG S6. The sigmoid Emax model was used to provide 24 h area under concentration-time curve/minimum inhibitory concentration ratios (AUC0-24h/MIC) for mycoplasmastasis, mycoplasmacidal activity and mycoplasmal elimination, respectively. The inoculum size and micro or macro methods exhibited little effect on MIC determination of MG, whereas matrix had a large effect. The rapid killing activity observed in in vitro time-killing curves seems to indicate that valnemulin was mycoplasmacidal and concentration dependent against MG. The AUC0-24h/MIC ratio for mycoplasmacidal activity and mycoplasmal elimination was 1321 h and 1960 h, respectively. A dosage regimen of 12.4 mg/kg/day and 18.3 mg/kg/day valnemulin was calculated for mycoplasmacidal activity and mycoplasmal elimination against MG S6, respectively.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chicken; Mycoplasma gallisepticum (MG); PK/PD; Valnemulin

Mesh:

Substances:

Year:  2015        PMID: 25744809     DOI: 10.1016/j.tvjl.2015.01.020

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  12 in total

1.  In vivo pharmacokinetic/pharmacodynamic profiles of valnemulin in an experimental intratracheal Mycoplasma gallisepticum infection model.

Authors:  Xia Xiao; Jian Sun; Tao Yang; Xi Fang; Dong Wu; Yan Q Xiong; Jie Cheng; Yi Chen; Wei Shi; Ya-Hong Liu
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

2.  Determination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and Valnemulin.

Authors:  Nan Zhang; Xiaomei Ye; Yuzhi Wu; Zilong Huang; Xiaoyan Gu; Qinren Cai; Xiangguang Shen; Hongxia Jiang; Huanzhong Ding
Journal:  PLoS One       Date:  2017-01-04       Impact factor: 3.240

3.  The PK-PD Relationship and Resistance Development of Danofloxacin against Mycoplasma gallisepticum in An In Vivo Infection Model.

Authors:  Nan Zhang; Yuzhi Wu; Zilong Huang; Lihua Yao; Longfei Zhang; Qinren Cai; Xiangguang Shen; Hongxia Jiang; Huanzhong Ding
Journal:  Front Microbiol       Date:  2017-05-30       Impact factor: 5.640

4.  In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens.

Authors:  Xia Xiao; Lijie Jiang; Weixuan Lan; Yongjia Jiang; Zhiqiang Wang
Journal:  BMC Vet Res       Date:  2018-11-29       Impact factor: 2.741

Review 5.  Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents.

Authors:  Wanhe Luo; Dongmei Chen; Mengru Wu; Zhenxia Li; Yanfei Tao; Qianying Liu; Yuanhu Pan; Wei Qu; Zonghui Yuan; Shuyu Xie
Journal:  J Vet Sci       Date:  2019-09       Impact factor: 1.672

6.  Co-infection of Mycoplasma gallisepticum and Escherichia coli Triggers Inflammatory Injury Involving the IL-17 Signaling Pathway.

Authors:  Zhiyong Wu; Liangjun Ding; Jiaxin Bao; Yuhao Liu; Qiaomei Zhang; Jian Wang; Rui Li; Muhammad Ishfaq; Jichang Li
Journal:  Front Microbiol       Date:  2019-11-15       Impact factor: 5.640

7.  Arachidonic acid metabolism is elevated in Mycoplasma gallisepticum and Escherichia coli co-infection and induces LTC4 in serum as the biomarker for detecting poultry respiratory disease.

Authors:  Zhiyong Wu; Chunli Chen; Qiaomei Zhang; Jiaxin Bao; Qianqian Fan; Rui Li; Muhammad Ishfaq; Jichang Li
Journal:  Virulence       Date:  2020-01-01       Impact factor: 5.882

8.  Tissue Residues and Pharmacokinetic/Pharmacodynamic Modeling of Tiamulin Against Mycoplasma anatis in Ducks.

Authors:  Sara T Elazab; Nahla S Elshater; Yousreya H Hashem; Seung-Chun Park; Walter H Hsu
Journal:  Front Vet Sci       Date:  2020-11-27

9.  The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum.

Authors:  Nan Zhang; Xiaoyan Gu; Xiaomei Ye; Xun Wu; Bingxu Zhang; Longfei Zhang; Xiangguang Shen; Hongxia Jiang; Huanzhong Ding
Journal:  Front Microbiol       Date:  2016-05-04       Impact factor: 5.640

10.  Antibiotic susceptibility profiles of Mycoplasma sp. 1220 strains isolated from geese in Hungary.

Authors:  Dénes Grózner; Zsuzsa Kreizinger; Kinga M Sulyok; Zsuzsanna Rónai; Veronika Hrivnák; Ibolya Turcsányi; Szilárd Jánosi; Miklós Gyuranecz
Journal:  BMC Vet Res       Date:  2016-08-19       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.